Analysis of MicroRNA expression profile identifies novel biomarkers for non-small cell lung cancer

Tumori

Volumn 101, Issue 1, 2015, Pages 104-110

  Xu, Chi ^a   Zheng, Yisheng ^a   Lian, Duohuang ^a   Ye, Shixin ^a   Yang, Jinrong ^a   Zeng, Zhiyong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

MicroRNA; Network analysis; NSCLC; Pathway enrichment

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 22; MICRORNA 34B; MICRORNA 448; MICRORNA 520H; MICRORNA 654 3P; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; MIRN22 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN; MIRN448 MICRORNA, HUMAN; MIRN520 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN TISSUE; MALE; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; NOTCH1 GENE; PATHOGENESIS; PTEN GENE; RNA ANALYSIS; UPREGULATION; VEGFA GENE; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; PROTEIN MICROARRAY;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930730253     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000224     Document Type: Article

References (58)

1. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol. 2012;30(22):2739-2744.
2. Kesanakurti D, Maddirela DR, Chittivelu S, Rao JS, Chetty C. Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer. Biochem Biophys Res Commun. 2013;434(3):627-633.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-862.
5. Bartel DP. Micro RNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
6. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013;382(9893):732-741.
7. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7(6):759-764.
8. Fontana L, Fiori ME, Albini S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE. 2008;3(5):e2236.
9. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775-789.
10. Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti- oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci. 2010;114(3):276-280.
11. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009;15(4): 1177-1183.
12. Hansen T, Olsen L, Lindow M, et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE. 2007;2(9):e873.
13. Ma L, Huang Y, Zhu W, et al. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS ONE. 2011;6(10):e26502.
14. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
15. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37(Database issue):D105-D110.
16. Hsu SD, Lin FM, Wu WY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163-D169.
17. Willis RC, Hogue CWV. Searching, viewing, and visualizing data in the Biomolecular Interaction Network Database (BIND)[J]. Current protocols in bioinformatics. 2006;8.9.1-8.9.30.
18. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
19. Hulsegge I, Kommadath A, Smits MA. Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc, 3 Suppl 4: S10, 2009.
20. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B. 1995;Series B (Methodological):289-300.
22. Kosaka N, Takeshita F, Yoshioka Y, et al. Therapeutic Application of MicroRNAs in Cancer[M]//RNA Interference from Biology to Therapeutics. Springer US, 2013:299-314.
23. Campayo M, Navarro A, Viñolas N, et al. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS ONE. 2011;6(7):e22509.
24. Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123-4132.
25. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther. 2008;7(8): 1288-1296.
26. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR- 34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8(1):266.
27. Majid S, Dar AA, Saini S, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2013;19(1):73-84.
28. Lee Y-M, Lee J-Y, Ho C-C, et al. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res. 2011;13(6):R116
29. Wang F, Xue X, Wei J, et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer. 2010;103(4):567-574.
30. Yu YH, Chen HA, Chen PS, et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene. 2013;32(4):431-443.
31. Chang YW, Hung MC, Su JL. The anti-tumor activity of E1A and its implications in cancer therapy. Arch Immunol Ther Exp (Warsz). 2014;62(3):195-204.
32. Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009;279(1):8-12.
33. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA. 2007;104(9):3219-3224.
34. Lilly B, Kennard S. Differential gene expression in a coculture model of angiogenesis reveals modulation of select pathways and a role for Notch signaling. Physiol Genomics. 2009;36(2):69-78.
35. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thrombosis and Haemostasis-Stuttgart- 2003;89: 177-184.
36. Jantus-Lewintre E, Sanmartín E, Sirera R, et al. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011;74(2):326-331.
37. Licciulli S, Avila JL, Hanlon L, et al. Notch1 is required for Krasinduced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 2013;73(19):5974-5984.
38. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70(23): 9937-9948.
39. Wang L, Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene. 2012;31(20): 2499-2511.
40. Li QQ, Chen ZQ, Xu JD, et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010;101(1):80-86.
41. Mao L, Yang C, Wang J, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013;11(1):111.
42. Wang M, Yin B, Matsueda S, et al. Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy. PLoS One. 2013;8(2):e56730.
43. Selinger CI, Cooper WA, Al-Sohaily S, et al. Loss of special ATrich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6(7):1179-1189.
44. Li QQ, Chen ZQ, Cao XX, et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelialmesenchymal transition of breast cancer cells. Cell Death Differ. 2011;18(1):16-25.
45. Ling B, Wang G-X, Long G, Qiu J-H, Hu Z-L. Tumor suppressor miR-22 suppresses lung cancer cell progression through posttranscriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012;138(8):1355-1361.
46. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res. 1997;88(1): 72-81.
47. Lei L, Huang Y, Gong W. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013;30(6):2897-2902.
48. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2013;372(1-2):35-45.
49. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61(1): 249-255.
50. Soria J-C, Lee H-Y, Lee JI, et al. Lack of PTEN expression in nonsmall cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8(5):1178-1184.
51. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11-12):846-852.
52. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/ Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226-235.
53. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8(3):187-198.
54. Chen JS, Wang Q, Fu XH, et al. Involvement of PI3K/PTEN/AKT/ mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res. 2009;39(2): 177-186.
55. Formosa A, Markert EK, Lena AM, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32. 31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2013; 33(44):5173-5182.
56. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG Jr Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol. 1996;16(12):6623-6633.
57. Wang H, Zhu LJ, Yang YC, Wang ZX, Wang R. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating Gi/S transition and apoptosis by targeting p21 (WAF1/CIP1). Br J Cancer. 2014;111(2):339-354.
58. Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS. Induction of p21 (Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J Agric Food Chem. 2014;62(9):2085-2095.